Clinically Relevant Reduction in Persistent Facial Erythema of Rosacea on the First Day of Treatment With Oxymetazoline Cream 1.0%

June 2018 | Volume 17 | Issue 6 | Original Article | 621 | Copyright © 2018

Emil A. Tanghetti MD,a Jeffrey S. Dover MD FRCPC,b David J. Goldberg MD,c Sunil S. Dhawan MD,d Lei Luo MPH,e David R. Berk MD,e Gurpreet Ahluwalia PhD,e and Nancy Alvandi PhDe

aCenter for Dermatology & Laser Surgery, Sacramento, CA bSkinCare Physicians, Chestnut Hill, MA cSkin Laser & Surgery Specialists of NY & NJ, New York, NY dCenter for Dermatology Clinical Research, Inc, Fremont, CA eAllergan plc, Irvine, CA

Abstract

BACKGROUND: Persistent facial erythema is a clinically challenging feature of rosacea. OBJECTIVE: To evaluate persistent erythema reduction on the first day of treatment from pooled data from two pivotal trials of topical oxymetazoline cream 1.0% (oxymetazoline) in persistent facial erythema of rosacea. METHODS: In two identically designed, phase 3, multicenter trials, adults with moderate to severe persistent facial erythema of rosacea (Clinician Erythema Assessment [CEA] grade ≥3 and Subject Self-Assessment [SSA] grade ≥3) were randomized 1:1 to once-daily topical oxymetazoline or vehicle; the primary efficacy endpoint was ≥2-grade composite CEA and SSA improvement from baseline on day 29. This post hoc analysis evaluated the proportion of patients achieving ≥1-grade composite and individual CEA and SSA improvement at 1, 3, 6, 9, and 12 hours postdose on day 1 (N=885). RESULTS: Significantly more patients achieved ≥1-grade composite and individual CEA and SSA improvement with the first application of oxymetazoline than with vehicle (P less than 0.001) at all postdose time points, beginning with hour 1. Day 1 safety assessments were similar between treatments. LIMITATIONS: Short-term, post hoc analysis. CONCLUSIONS: A ≥1-grade improvement in persistent erythema achieved after the first dose of once-daily topical oxymetazoline demonstrated clinically meaningful improvement from the beginning of therapy. J Drugs Dermatol. 2018;17(6):621-626.

Purchase Original Article

Purchase a single fully formatted PDF of the original manuscript as it was published in the JDD.

Download the original manuscript as it was published in the JDD.

Contact a member of the JDD Sales Team to request a quote or purchase bulk reprints, e-prints or international translation requests.

To get access to JDD's full-text articles and archives, upgrade here.

Save an unformatted copy of this article for on-screen viewing.

Print the full-text of article as it appears on the JDD site.

→ proceed | ↑ close

INTRODUCTION

Rosacea is a chronic dermatologic disease that affects approximately 16 million people in the United States.1,2 Its features include centrofacial persistent erythema, flushing, telangiectasia, and/or papules and pustules.3-5Persistent facial erythema is the most common, bothersome, and therapeutically challenging feature of rosacea.3,6-9 Most approved topical pharmacologic agents for rosacea reduce the papules and pustules but are unable to address persistent erythema. They lack the appropriate mechanism to target the underlying fixed changes in superficial cutaneous vasculature, which are regulated by adrenoceptors at the neuromuscular junction that mediate vasoconstriction and vasodilation.7,10-13 Most patients prefer rosacea therapies that show a rapid and noticeable clinical benefit for persistent erythema from the beginning of therapy. An immediate reduction of erythema may affect the likelihood that patients will continue with long-term treatment for this chronic disease.7,8,14,15In 2017, the US Food and Drug Administration (FDA) approved oxymetazoline hydrochloride cream 1.0% (oxymetazoline; Rhofade™, Allergan plc, Dublin, Ireland), the first α1A-adrenoceptor agonist that causes vasoconstriction of the cutaneous microvasculature, for the topical treatment of persistent facial erythema associated with rosacea in adults.10,16,17 Data from two identically designed, phase 3, pivotal, vehicle-controlled trials (REVEAL) demonstrated that oxymetazoline applied topically once daily for 29 days significantly reduced moderate to severe persistent facial erythema of rosacea at 3, 6, 9, and 12 hours postdose on day 29 and was safe and well tolerated over 4 weeks.18,19 The primary efficacy endpoint of these studies was a 2-grade or greater composite improvement from baseline scores on the Clinician Erythema Assessment (CEA) scale with photonumeric guide and Subject Self-Assessment for rosacea facial redness (SSA) scale with photo guide. Although the 2-grade or greater composite clinician- and patient-assessed improvement in rosacea facial redness satisfies FDA criteria for rosacea indication approval, this outcome is not the only clinically

↑ back to top


Related Articles